Inicio › Dermatitis atópica (eccema) › Illinois
Ensayos clínicos de Dermatitis atópica (eccema) en Illinois
10 estudios sobre Dermatitis atópica (eccema) buscan participantes en Illinois.
Ciudades en Illinois
Texto oficial del estudio (inglés)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Sneeze, Wheeze, & Itch Associates, LLC- Site Number : 8400029, Normal
- Rosalind Franklin University of Medicine and Science- Site Number: 8400056, North Chicago
ReclutandoEstudio observacional
Edades de 12 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Chicago
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Skokie
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07003425A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Endeavor Health, Skokie
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 28 ago 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 2, Rolling Meadows
ReclutandoFase 2
Edades de 18 a 74 · Todos los sexos · Actualizado el 12 ago 2026 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Northwestern University Feinberg School of Medicine /ID# 265117, Chicago
- Sneeze Wheeze & Itch Associates /ID# 267238, Normal
ReclutandoFase 3
Edades de 2 a 11 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- DeNova Research /ID# 264513, Chicago
- Northwestern University Feinberg School of Medicine /ID# 264983, Chicago
ReclutandoFase 3
Edades de 18 a 63 · Todos los sexos · Actualizado el 6 jul 2026 · NCT06389136Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
- Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago
ReclutandoFase 1
Edades de 6 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT06504160Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
- Lurie Children's Hospital/Northwestern University, Chicago
ReclutandoFase 4
Edades de 6 a 17 · Todos los sexos · Actualizado el 27 abr 2026 · NCT05042258Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7058, Chicago
ReclutandoEstudio observacional
Edades de 12 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT06988605De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.